An analysis of FDA-approved drugs for infectious disease: antibacterial agents

The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America

Spellberg, B. J., Guidos, R., Gilbert, D. N., Bradley, J. S., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J. E., & the Infectious Diseases Society of America (2007) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,647 · see citing works

Sampling the Antibiotic Resistome

D'Costa, V. M., McGrann, K. M., Hughes, D. W., & Wright, G. D. (2006) · Science · doi:10.1126/science.1120800 · Cited by 1,594 · see citing works

Platforms for antibiotic discovery

Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,449 · see citing works

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals

Shlaes, D. M., Gerding, D. N., John, J. F., Craig, W. A., Bornstein, D. L., Duncan, R. A., Eckman, M. R., Farrer, W. E., Greene, W. H., Lorian, V., et al. (1997) · Clinical Infectious Diseases · doi:10.1086/513766 · Cited by 781 · see citing works

Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

Infectious Diseases Society of America (IDSA) (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir153 · Cited by 734 · see citing works

The Burden of Disease and the Changing Task of Medicine

Jones, D. S., Podolsky, S. H., & Greene, J. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1113569 · Cited by 332 · see citing works

An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs

Kinch, M. S., & Patridge, E. V. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.012 · Cited by 59 · see citing works

Antibiotics in Animal Feeds—Human and Animal Safety Issues

Solomons, I. A. (1978) · Journal of Animal Science · doi:10.2527/jas1978.4651360x · Cited by 41 · see citing works

Cost‐Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

Laohavaleeson, S., Barriere, S. L., Nicolau, D. P., & Kuti, J. L. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.12.1471 · Cited by 22 · see citing works

Fidaxomicin for Clostridium difficile-Associated Diarrhoea

Sclar, D. A., Robison, L. M., Oganov, A. M., Schmidt, J. M., Bowen, K. A., & Castillo, L. V. (2012) · Clinical Drug Investigation · doi:10.1007/bf03261906 · Cited by 18 · see citing works

Sulfanilamide: A Review

SCHNITKER, M. A. (1938) · New England Journal of Medicine · doi:10.1056/nejm193803242181201 · Cited by 11 · see citing works

The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation

Langdon, A. E., Crook, N., & Dantas, G. A. (2016) · Genome Medicine · doi:10.1186/s13073-016-0294-z · Cited by 917 · see citing works

An analysis of FDA-approved drugs: natural products and their derivatives

Patridge, E. V., Gareiss, P. C., Kinch, M. S., & Hoyer, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.009 · Cited by 836 · see citing works

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815 · see citing works

Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring

Wang, Y., Beekman, J., Hew, J. J., Jackson, S. R., Issler‐Fisher, A. C., Parungao, R., Lajevardi, S. S., Li, Z., & Maitz, P. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.018 · Cited by 703 · see citing works

Nanotechnology approaches for global infectious diseases

Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520 · see citing works

Natural Products as a Source for Novel Antibiotics

Moloney, M. G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.001 · Cited by 309 · see citing works

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

Butler, M. S., Gigante, V., Sati, H., Paulin, S., Al-Sulaiman, L., Rex, J. H., Fernandes, P., Arias, C. A., Paul, M., Thwaites, G. E., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01991-21 · Cited by 257 · see citing works

Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 267 · see citing works

Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed

Butler, M. S., Gigante, V., Sati, H. F., Pastore, P., Al-Sulaiman, L., Rex, J. H., FERNANDES, P. B., Arias, C. A., Paul, M., Thwaites, G. E., et al. (2022) · Archive ouverte UNIGE (University of Geneva) · Cited by 218 · see citing works

Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning‐enabled molecular diagnostics

Khaledi, A., Weimann, A., Schniederjans, M., Asgari, E., Kuo, T., Oliver, A., Cabot, G., Kola, A., Gastmeier, P., Hogardt, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910264 · Cited by 204 · see citing works

Plasticity, dynamics, and inhibition of emerging tetracycline resistance enzymes

Park, J., Gasparrini, A. J., Reck, M. R., Symister, C. T., Elliott, J. L., Vogel, J. P., Wencewicz, T. A., Dantas, G. A., & Tolia, N. H. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2376 · Cited by 146 · see citing works

Nanozybiotics: advancing antimicrobial strategies through biomimetic mechanisms

Zhou, C., Wang, Q., Cao, H., Jiang, J., & Gao, L. (2024) · Advanced Materials · doi:10.1002/adma.202403362 · Cited by 114 · see citing works

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach

Rex, J. H., & Outterson, K. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00500-9 · Cited by 113 · see citing works

Discovery and Characterization of a Nitroreductase Capable of Conferring Bacterial Resistance to Chloramphenicol

Crofts, T. S., Sontha, P., King, A. O., Wang, B., Biddy, B. A., Zanolli, N. C., Gaumnitz, J., & Dantas, G. A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.01.007 · Cited by 84 · see citing works

Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram‐Negative Pathogens

Hüttel, S., Testolin, G., Herrmann, J. E., Planke, T., Gille, F., Moreno, M., Stadler, M., Brönstrup, M., Kirschning, A., & Müller, R. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201705913 · Cited by 80 · see citing works

One cannot rule them all: Are bacterial toxins-antitoxins druggable?

Chan, W. T., Balsa, D., & Espinosa, M. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuv002 · Cited by 75 · see citing works

New antibiotics from Nature’s chemical inventory

Wencewicz, T. A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.09.014 · Cited by 69 · see citing works

Introduction and geographic availability of new antibiotics approved between 1999 and 2014

Kållberg, C., Årdal, C., Blix, H. S., Klein, E. Y., Martinez, E. M., Lindbæk, M., Outterson, K., Røttingen, J., & Laxminarayan, R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205166 · Cited by 69 · see citing works

Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms

Ahmed, S., Ahmed, M. Z., Rafique, S., Almasoudi, S. E., Shah, M., Jalil, N. A. C., & Ojha, S. C. (2023) · BioMed Research International · doi:10.1155/2023/5250040 · Cited by 75 · see citing works

Catalytic antimicrobial therapy using nanozymes

Wang, Q., Jiang, J., & Gao, L. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1769 · Cited by 67 · see citing works

Evaluation of burn wound healing activity of novel fusidic acid loaded microemulsion based gel in male Wistar albino rats

Okur, M. E., Ayla, Ş., Yozgatlı, V., Aksu, B., Yoltaş, A., Orak, D., Si̇pahi̇, H., & Okur, N. Ü. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.01.015 · Cited by 62 · see citing works

Hybrid antibiotics – clinical progress and novel designs

Parkes, A. L., & Yule, I. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1187597 · Cited by 61 · see citing works

Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs

Douguet, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00462 · Cited by 59 · see citing works

Ferrocenyl chalcone derivatives as possible antimicrobial agents

Henry, E. J., Bird, S. J., Gowland, P., Collins, M., & Cassella, J. P. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0280-y · Cited by 64 · see citing works

Sensitization of Gram-negative bacteria to rifampin and OAK combinations

Jammal, J., Zaknoon, F., Kaneti, G., Goldberg, K., & Mor, A. (2015) · Scientific Reports · doi:10.1038/srep09216 · Cited by 55 · see citing works

Preparation and evaluation of QbD based fusidic acid loaded in situ gel formulations for burn wound treatment

Aksu, B., Yozgatlı, V., Okur, M. E., Ayla, Ş., Yoltaş, A., & Okur, N. Ü. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.04.015 · Cited by 55 · see citing works

Bacteriophage Clinical Use as Antibacterial “Drugs”: Utility and Precedent

Abedon, S. T. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0003-2016 · Cited by 51 · see citing works

Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery

Espinoza-Chávez, R. M., Salerno, A., Liuzzi, A., Ilari, A., Milelli, A., Uliassi, E., & Bolognesi, M. L. (2022) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00063 · Cited by 50 · see citing works

Single-cell pathogen diagnostics for combating antibiotic resistance

Li, H., Hsieh, K., Wong, P. K., Mach, K. E., Liao, J. C., & Wang, T. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00190-y · Cited by 50 · see citing works

Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing

Madugula, S. S., John, L., Nagamani, S., Gaur, A. S., Poroikov, V., & Sastry, G. N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104856 · Cited by 45 · see citing works

Genomic and functional techniques to mine the microbiome for novel antimicrobials and antimicrobial resistance genes

Adu‐Oppong, B., Gasparrini, A. J., & Dantas, G. A. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13257 · Cited by 44 · see citing works

Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections

Ng, S. M. S., Sioson, J. S. P., Yap, J. M., Ng, F. M., Ching, H. S. V., Teo, J. W. P., Jureen, R., Hill, J., & Chia, C. S. B. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3114-5 · Cited by 44 · see citing works

Radiopharmaceutical enhancement by drug delivery systems: A review

Kleynhans, J., Grobler, A., Ebenhan, T., Sathekge, M. M., & Zeevart, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.008 · Cited by 41 · see citing works

Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations

Årdal, C., Enrico Baraldi, A., Theuretzbacher, U., Outterson, K., Plahte, J., Ciabuschi, F., & Røttingen, J. (2018) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-018-0135-0 · Cited by 40 · see citing works

Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus

Lim, C. S. Q., Ha, K. P., Clarke, R. S., Gavin, L.-A., Cook, D. T., Hutton, J. A., Sutherell, C. L., Edwards, A. M., Evans, L. E., Tate, E. W., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.06.025 · Cited by 33 · see citing works

Antibiotics: From Mechanism of Action to Resistance and Beyond

Saikia, S., & Chetia, P. (2024) · Indian Journal of Microbiology · doi:10.1007/s12088-024-01285-8 · Cited by 38 · see citing works

PROPHETIC

Bergin, S. P., Coles, A., Calvert, S. B., Farley, J. J., Powers, J. H., Zervos, M., Sims, M. D., Kollef, M. H., Durkin, M. J., Kabchi, B. A., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.06.034 · Cited by 30 · see citing works

Targeting the Bacterial SOS Response for New Antimicrobial Agents: Drug targets, Molecular Mechanisms and Inhibitors

Lanyon‐Hogg, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0310 · Cited by 29 · see citing works

Target selection for FDA-approved medicines

Kinch, M. S., Hoyer, D., Patridge, E. V., & Plummer, M. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.11.001 · Cited by 30 · see citing works

Decoding antibiotic resistance in Pseudomonas aeruginosa: Embracing innovative therapies beyond conventional antibiotics

Gupta, N., Chauhan, K., Singh, G., Chaudhary, S., & Rathore, J. S. (2025) · The Microbe · doi:10.1016/j.microb.2025.100233 · Cited by 29 · see citing works

Preliminary view of the global distribution and spread of the tet(X) family of tigecycline resistance genes

Pan, Y., Awan, F., Ma, Z.-B., Zhang, X., Zeng, J., Zeng, Z., & Xiong, W. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa284 · Cited by 29 · see citing works

Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system

Lv, Q., Li, S., Wei, H., Wen, Z., Wang, Y., Tang, T., Wang, J., Xia, L., & Deng, X. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10290-7 · Cited by 26 · see citing works

Time-constrained interactions in public-private collaboration projects. The case of ENABLE

Kronlid, C., & Enrico Baraldi, A. (2020) · Journal of Business and Industrial Marketing · doi:10.1108/jbim-05-2019-0221 · Cited by 26 · see citing works

Challenges and Solutions for Clinical Development of New Antibacterial Agents: Results of a Survey among Pharmaceutical Industry Professionals

Bettiol, E., Wetherington, J. D., Schmitt, N., & Harbarth, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00638-15 · Cited by 26 · see citing works

Combinatorial nanodroplet platform for screening antibiotic combinations

Li, H., Zhang, P., Hsieh, K., & Wang, T. (2022) · Lab on a Chip · doi:10.1039/d1lc00865j · Cited by 23 · see citing works

Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole‐resistant Candida albicans

Ng, S. M. S., Yap, Y. Y. A., Cheong, J. W. D., Ng, F. M., Lau, Q. Y., Barkham, T., Teo, J. W. P., Hill, J., & Chia, C. S. B. (2017) · Journal of Peptide Science · doi:10.1002/psc.2970 · Cited by 23 · see citing works

Development of new antibiotics: taking off finally?

Bettiol, E., & Harbarth, S. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14167 · Cited by 22 · see citing works

Bacteriophage versus antibiotic therapy on gut bacterial communities of juvenile green turtle, Chelonia mydas

Ahasan, M. S., Kinobe, R. T., Elliott, L., Owens, L., Scott, J. L., Picard, J., Huerlimann, R., & Ariel, E. (2019) · Environmental Microbiology · doi:10.1111/1462-2920.14644 · Cited by 22 · see citing works

Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation

O’Jeanson, A., Larcher, R., Souder, C. L., Djebli, N., & Khier, S. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00709-w · Cited by 22 · see citing works

Coumarin-1,2,3-triazole hybrids as leading-edge anticancer agents

Mishra, K. N., & Upadhyay, H. C. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1072448 · Cited by 22 · see citing works

Why to Study Peptides from Venomous and Poisonous Animals?

de Oliveira, A. L. N., Soares, A. M., & Silva, S. L. D. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10543-0 · Cited by 22 · see citing works

Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases

Hrast, M., Rožman, K., Ogris, I., Škedelj, V., Patin, D., Sova, M., Barreteau, H., Gobec, S., Grdadolnik, S. G., & Zega, A. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1608981 · Cited by 21 · see citing works

Protecting human security: proposals for the G7 Ise-Shima Summit in Japan

† (2016) · The Lancet · doi:10.1016/s0140-6736(16)30177-5 · Cited by 19 · see citing works

Public Funding of Clinical-Stage Antibiotic Development in the United States and European Union

Eichberg, M. J. (2015) · Health Security · doi:10.1089/hs.2014.0081 · Cited by 19 · see citing works

Pyroptosis of Salmonella Typhimurium-infected macrophages was suppressed and elimination of intracellular bacteria from macrophages was promoted by blocking QseC

Li, Z., Zheng, Q. Y., Xue, X., Shi, X., Zhou, Y., Da, F., Qu, D., Hou, Z., & Luo, X. (2016) · Scientific Reports · doi:10.1038/srep37447 · Cited by 19 · see citing works

Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?

Akhmetov, I., & Bubnov, R. V. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0078-6 · Cited by 18 · see citing works

Compound design guidelines for evading the efflux and permeation barriers of Escherichia coli with the oxazolidinone class of antibacterials: Test case for a general approach to improving whole cell Gram-negative activity

Spaulding, A. E., Takrouri, K., Mahalingam, P., Cleary, D. C., Cooper, H. D., Zucchi, P., Tear, W. F., Koleva, B. N., Beuning, P. J., Hirsch, E. B., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.018 · Cited by 18 · see citing works

Elucidating the bactericidal mechanism of action of the linear antimicrobial tetrapeptide BRBR-NH2

Lau, Q. Y., Li, J., Sani, M., Sinha, S., Li, Y., Ng, F. M., Kang, C., Bhattacharjya, S., Separovic, F., Verma, C. S., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.05.004 · Cited by 18 · see citing works

An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)

Lau, Q. Y., Tan, Y. Y. F., Goh, V., Lee, D., Ng, F. M., Ong, E. H., Hill, J., & Chia, C. S. B. (2015) · Antibiotics · doi:10.3390/antibiotics4040424 · Cited by 18 · see citing works

Joining Forces to Prevent the Antibiotic Resistance Doomsday Scenario: The Rise of International Multisectoral Partnerships as a New Governance Model

Ciabuschi, F., Enrico Baraldi, A., & Lindahl, O. (2020) · Academy of Management Perspectives · doi:10.5465/amp.2019.0018 · Cited by 17 · see citing works

Mimics of pramanicin derived from pyroglutamic acid and their antibacterial activity

Tan, S., Chai, C. L. L., & Moloney, M. G. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob02828d · Cited by 17 · see citing works

Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria

Gerasyuto, A. I., Arnold, M. A., Wang, J., Chen, G., Zhang, X., Smith, S. W., Woll, M. G., Baird, J. D., Zhang, N., Almstead, N. G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00114 · Cited by 17 · see citing works

Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can … Now We Need to Start Pulling!

Rex, J. H., & Outterson, K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa852 · Cited by 17 · see citing works

Entdeckung und Totalsynthese von natürlichen Cystobactamid‐Derivaten mit herausragender Aktivität gegen Gram‐negative Pathogene

Hüttel, S., Testolin, G., Herrmann, J. E., Planke, T., Gille, F., Moreno, M., Stadler, M., Brönstrup, M., Kirschning, A., & Müller, R. (2017) · Angewandte Chemie · doi:10.1002/ange.201705913 · Cited by 16 · see citing works

Managing interorganizational interactions for social impact: A study of two antibiotics R&D networks

Enrico Baraldi, A., Ciabuschi, F., Kronlid, C., & Lindahl, O. (2021) · Journal of Business Research · doi:10.1016/j.jbusres.2021.12.027 · Cited by 15 · see citing works

Small at Size, Big at Impact: Microorganisms for Sustainable Development

Singh, N., Singh, J., & Singh, K. (2018) · Springer eBooks · doi:10.1007/978-981-13-0053-0_1 · Cited by 15 · see citing works

Synthesis and biological evaluation of ruthenium complexes bearing the 1,2,4-triazole group as potential membrane-targeting antibacterial agents towards Staphylococcus aureus

Wang, P., Huang, H., Dou, L.-X., Deng, W., Wang, J., Liao, X., Yu, R.-J., Duan, X., & Xiong, Y. (2023) · Dalton Transactions · doi:10.1039/d3dt00889d · Cited by 13 · see citing works

A peptide targeting outer membrane protein A of Acinetobacter baumannii exhibits antibacterial activity by reducing bacterial pathogenicity

Zhao, H., Hu, Y., Nie, D., Chen, Z., Chen, Z., Zhou, S., Li, M., & Xue, X. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00565-24 · Cited by 13 · see citing works

4-Hydroxy-2-pyridones: Discovery and evaluation of a novel class of antibacterial agents targeting DNA synthesis

Arnold, M. A., Gerasyuto, A. I., Wang, J., Du, W., Gorske, Y. J. K., Arasu, T., Baird, J. D., Almstead, N. G., Narasimhan, J., Peddi, S. R., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.006 · Cited by 13 · see citing works

Bioguided Identification of Antimicrobial Compounds from Chrysopogon Zizaniodes (L.) Roberty Root Essential Oil

Rueda, R. Y. R., Marinho, J. V. N., & Salvador, M. J. (2019) · Future Microbiology · doi:10.2217/fmb-2019-0167 · Cited by 13 · see citing works

Applying the resource interaction approach to policy analysis – Insights from the antibiotic resistance challenge

Enrico Baraldi, A., & Wagrell, S. (2022) · Industrial Marketing Management · doi:10.1016/j.indmarman.2022.09.012 · Cited by 12 · see citing works

Antibacterial New Target Discovery: Sentinel Examples, Strategies, and Surveying Success

Sutterlin, H. A., Malinverni, J. C., Lee, S. H., Balibar, C. J., & Roemer, T. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_31 · Cited by 12 · see citing works

Applied physiology: gut microbiota and antimicrobial therapy

Suslov, A. V., Panas, A., Sinelnikov, M. Y., Maslennikov, R. V., Trishina, A. S., Zharikova, T. S., Zharova, N. V., Kalinin, D. V., Pontes‐Silva, A., & Zharikov, Y. O. (2024) · European Journal of Applied Physiology · doi:10.1007/s00421-024-05496-1 · Cited by 11 · see citing works

A Clinical Trial to Evaluate the Efficacy of α-Viniferin in Staphylococcus aureus – Specific Decolonization without Depleting the Normal Microbiota of Nares

RAHIM, M. A., Seo, H., Kim, S., Jeong, Y. K., Tajdozian, H., Kim, M., Lee, S., & Song, H. (2021) · Polish Journal of Microbiology · doi:10.33073/pjm-2021-011 · Cited by 11 · see citing works

Synthesis and antibacterial activity of new symmetric polyoxygenated dibenzofurans

Oramas‐Royo, S., Pantoja, K. D., Amesty, Á., Romero, C., Lorenzo-Castrillejo, I., Machín, F., & Estévez‐Braun, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.062 · Cited by 10 · see citing works

Innovative nanotechnology for infectious and inflammatory disease control: From diagnostics to therapeutics

Khosravi, F., Rahmani, P., & Jahanban‐Esfahlan, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118551 · Cited by 12 · see citing works

An analysis of FDA-approved drugs for cardiovascular diseases

Kinch, M. S., Surovtseva, Y. V., & Hoyer, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.001 · Cited by 9 · see citing works

Equisetin, Reutericyclin and Streptolodygin as Natural Product Lead Structures for Novel Antibiotic Libraries

Jeong, Y., & Moloney, M. G. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.97 · Cited by 9 · see citing works

Synthesis of novel 3-[(2R*)-2-[(2S*)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-2-hydroxyethyl]-urea/thiourea derivatives and evaluation of their antimicrobial activities

Mannam, M. R., Srimurugan, S., Kumar, P., Raju, C. N., & Prasad, K. R. S. (2019) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2019.1635596 · Cited by 9 · see citing works

Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development

Enrico Baraldi, A., Ciabuschi, F., Leach, R., Morel, C. M., & Waluszewski, A. (2016) · American Journal of Law & Medicine · doi:10.1177/0098858816658276 · Cited by 8 · see citing works

Spirocyclic Tetramates by Sequential Knoevenagel and [1,5]-Prototropic Shift

Josa‐Culleré, L., Hirst, M. G., Lockett, J. P., Thompson, A. L., & Moloney, M. G. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b01345 · Cited by 8 · see citing works

Antibiotic Development: Lessons from the Past and Future Opportunities

Kinch, M. S., Kraft, Z., & Schwartz, T. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03694-2 · Cited by 7 · see citing works

Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator

Polański, J., Bogocz, J., & Tkocz, A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.015 · Cited by 7 · see citing works

A history of drug development in four acts

Kinch, M. S., & Hoyer, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.04.003 · Cited by 7 · see citing works

Attrition in Drug Discovery and Development

Boyer, S. K., BREALEY, C. J., & Davis, A. M. (2015) · doi:10.1002/9781118819586.ch1 · Cited by 7 · see citing works

Discovery of a fragment hit compound targeting D-Ala:D-Ala ligase of bacterial peptidoglycan biosynthesis

Proj, M., Hrast, M., Bajc, G., Frlan, R., Meden, A., Butala, M., & Gobec, S. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2149745 · Cited by 6 · see citing works

Sub-inhibitory membrane damage undermines Staphylococcus aureus virulence

Hershkovits, A. S., Pozdnyakov, I., Meir, O., & Mor, A. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.04.002 · Cited by 6 · see citing works

The Decline of Innovation in the Antibiotics Industry and the Global Threat of Antibiotic Resistance: When Entrepreneurial Efforts are Not Enough

Ciabuschi, F., & Lindahl, O. (2018) · Studies on entrepreneurship, structural change and industrial dynamics · doi:10.1007/978-3-319-89336-5_9 · Cited by 5 · see citing works

The Microbiome: A Reservoir to Discover New Antimicrobials Agents

Boutin, S., & Dalpke, A. H. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200320112731 · Cited by 5 · see citing works

Increase Development and Decrease Use! Innovation Controversies Caused by Antimicrobial Resistance

Waluszewski, A., Enrico Baraldi, A., & Ciabuschi, F. (2017) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-137-55780-3_12 · Cited by 5 · see citing works

Lipid Engineered Nanoparticle Therapy for Burn Wound Treatment

Beg, S., Qadir, A., Ahmad, U., Ali, A., Shahid, A., Aqil, M., Khan, N., Ali, A., Almalki, W. H., Alghamdi, S. A., et al. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210823110532 · Cited by 4 · see citing works

In vitro research of combination therapy for multidrug-resistant Klebsiella pneumoniae bloodstream infections

Sun, L., Sun, J., & Ding, S. (2022) · Journal of International Medical Research · doi:10.1177/03000605221106705 · Cited by 4 · see citing works

Trends in Drug Discovery over Five Decades – The European Federation for Medicinal Chemistry International Symposium on Medicinal Chemistry (EFMC−ISMC)

Differding, E. (2020) · ChemMedChem · doi:10.1002/cmdc.202000840 · Cited by 4 · see citing works

Bacteriophage Clinical Use as Antibacterial “Drugs”: Utility and Precedent

Abedon, S. T. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch19 · Cited by 4 · see citing works

Biotechnological Approaches in Infectious Diseases

Banerjee, S., Bose, S., Shukla, A. C., & Baig, M. R. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-1148-2_15 · Cited by 3 · see citing works

Liposomes for infectious diseases

Gkartziou, F., & Antimisiaris, S. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15491-1.00008-0 · Cited by 2 · see citing works

Post-approval fate of pharmaceutical companies

Kinch, M. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.013 · Cited by 3 · see citing works

Pediatric Infectious Diseases: Getting Research Evidence into Practice and Generation of New Evidence

Rostenberghe, H. V. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00138 · Cited by 2 · see citing works

Antibacterials

(2018) · Topics in medicinal chemistry · doi:10.1007/978-3-319-70839-3 · Cited by 2 · see citing works

Screening for a Potent Antibacterial Peptide to Treat Mupirocin-Resistant MRSA Skin Infections

Ng, S. M. S., Ching, H. S. V., Xu, G., Ng, F. M., Ong, E. H., Lau, Q. Y., Jureen, R., Hill, J., & Chia, C. S. B. (2017) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-017-9580-x · Cited by 2 · see citing works

Trends in antimicrobial drug development: Implications for the future

Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867 · see citing works

An Analysis of Antibacterial Drug Development Trends in the United States, 1980–2019

Dheman, N., Mahoney, N. M., Cox, E. M., Farley, J. J., Amini, T., & Lanthier, M. L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa859 · Cited by 58 · see citing works

Synthetic approaches and therapeutic applications of FDA-approved antibacterial agents: A comprehensive review from 2003 to 2023

Qiao, W., Wang, L., Luo, Y., & Yang, T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117267 · Cited by 15 · see citing works

Approved antibacterial drugs in the last 10 years: from the bench to the clinic

García-Castro, M., Sarabia, F., Díaz, A., & López‐Romero, J. M. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00013 · Cited by 27 · see citing works

Исследования в области новых антибактериальных средств есть ли перспективы

Колбин, А. С., Sv, S., & Ефимовна, Б. Ю. (2010) · Педиатрическая фармакология